Table 5.
Risk factors of nivolumab‐related pneumonitis in all the patients or ILD group
| N | Total | ILD group | |||||
|---|---|---|---|---|---|---|---|
| Pneumonitis − | Pneumonitis + | Pneumonitis − | Pneumonitis + | ||||
| 186 | 30 | P | 18 | 8 | P | ||
| Age ≥ 75 | 38 (20) | 4 (13) | 0.461 | 5 (28) | 1 (13) | 0.628 | |
| Gender (male) | 127 (68) | 27 (90) | 0.016 | 12 (67) | 8 (100) | 0.132 | |
| Current or former smoker | 143 (77) | 27 (90) | 0.148 | 17 (94) | 8 (100) | > 0.99 | |
| ECOG‐PS ≥ 2 | 51 (27) | 5 (17) | 0.265 | 8 (44) | 1 (13) | 0.19 | |
| Positive EGFR mutation | 38 (20) | 4 (13) | 0.461 | 0 (0) | 0 (0) | > 0.99 | |
| Comorbidity with RA | 7 (4) | 4 (13) | 0.05 | 4 (22) | 3 (38) | 0.635 | |
| Thoracic radiotherapy | 54 (29) | 9 (30) | >0.99 | 2 (11) | 1 (13) | > 0.99 | |
| Line of chemotherapy | Second | 69 (37) | 13 (43) | 0.547 | 13 (72) | 5 (63) | 0.667 |
| Third or later | 117 (63) | 17 (57) | 5 (28) | 3 (38) | |||
| CRP > 50 mg/l | 29 (16) | 3 (10) | 0.583 | 4 (22) | 0 (0) | 0.277 | |
| Total dose of nivolumab | 5.0 (1–30) | 6.0 (1–37) | 0.653 | 5.5 (1–30) | 5.0 (1–37) | 0.978 | |
| With preexisting ILD | 18 (10) | 8 (27) | 0.014 | ||||
| Radiographic pattern of | NSIP | 9 (50) | 5 (63) | 0.683 | |||
| preexisting ILD | UIP | 9 (50) | 3 (38) | ||||
P values were calculated by using Fisher's exact or Mann‐Whitney U tests where appropriate.
CRP, C‐reactive protein;
ECOG‐PS, Eastern Cooperative Oncology Group‐performance status; ILD, interstitial lung disease; NSIP, non‐specific interstitial pneumonia; RA, rheumatoid arthritis; UIP, usual interstitial pneumonia.